Key result
Treatment with the nucleoside viral polymerase inhibitor 2'-C-methylcytidine (2CMC) reduced murine norovirus shedding to undetectable levels without the emergence of drug-resistant variants.
Why the study?
Does 2'-C-methylcytidine reduce viral shedding in a mouse model of persistent norovirus infection?
Does 2'-C-methylcytidine reduce viral shedding in a mouse model of persistent norovirus infection?
The nucleoside polymerase inhibitor 2CMC effectively suppresses persistent norovirus shedding in a mouse model without inducing drug resistance.
Answers are grounded in this paper and cite their sources.
May inform norovirus antiviral development; leaves open translation to human persistent infection.
Prolonged norovirus shedding may occur in certain patients, such as organ transplant recipients. We established a mouse model for persistent norovirus infection (using the mouse norovirus MNV.CR6 strain). The nucleoside viral polymerase inhibitor 2'-C-methylcytidine (2CMC), but not favipiravir (T-705), reduced viral shedding to undetectable levels. Viral rebound was observed after stopping treatment, which was again effectively controlled by treatment with 2CMC. No drug-resistant variants emerged.
No takes yet. Share an insight, caveat, or question.
Rocha‐Pereira et al. (2015) studied Persistent norovirus infection. 2'-C-methylcytidine (2CMC) vs. favipiravir (T-705) was evaluated on Viral shedding in stool. Treatment with the nucleoside viral polymerase inhibitor 2'-C-methylcytidine (2CMC) reduced murine norovirus shedding to undetectable levels without the emergence of drug-resistant variants.
Synapse has enriched 10 related papers. Consider them for comparative context: